A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) (NCT02821013)

STOP-GAP

This trial is No longer recruiting
Registration number NCT02821013

Program & service

This trial is being run with the Cancer service, and as part of the Medical Oncology program.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Professor Mark Shackleton

Teletrial

This trial is being conducted as a teletrial.

A teletrial is where hospitals - regional, rural or city - share a clinical trial and work together to deliver it to their patients all at the same time. This means, for example, you may be on the same trial at your local hospital at the same time as someone 200km away at their local hospital. The entire medical team involved in the one trial use digital communication, such as video conferencing, to closely communicate with each other as one big team. This means you may now have more opportunities to go on a clinical trial at your nearest hospital. Find out more about teletrials at our telehub.

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.